MedPath

Glycemic Objectives of Women With Gestational Diabetes Mellitus

Phase 3
Terminated
Conditions
Gestational Diabetes Mellitus
Registration Number
NCT02478762
Lead Sponsor
Université de Sherbrooke
Brief Summary

In a previous study, the investigators established the dosage of foetal glycated hemoglobin (FGH). It represents the mean of blood sugar 4-6 before the delivery. The investigators also compared the FGH of newborn of women with and without gestational diabetes mellitus (GDM) and determined that newborn of women with GDM had significantly higher FGH that newborn of women without GDM.

In this study, the investigators want to compare the FGH of newborn of GDM women randomized to a group reaching the Canadian Diabetes Association recommended blood glucose objectives treatment (fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L) to a group reaching lower blood glucose objectives (fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L)

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
5
Inclusion Criteria
  • gestational age between 15 and 32 weeks since last menstrual date,
  • received education on gestational diabetes mellitus,
  • able to read and understand French.
Exclusion Criteria
  • known type 1 or type 2 diabetes,
  • treatment interfering woth glucose metabolism,
  • deficit may hinder the understanding of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Foetal glycated hemoglobinAt delivery
Secondary Outcome Measures
NameTimeMethod
Treatment satisfactionEnd of pregnancy

Evaluated by questionnaire

Trial Locations

Locations (1)

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

🇨🇦

Sherbrooke, Quebec, Canada

Centre de recherche du Centre hospitalier universitaire de Sherbrooke
🇨🇦Sherbrooke, Quebec, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.